Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Yttrium-90 beta radiation (Y-90)
- Target
- Y-90
- Molecular classification
- Other (radioisotope; radionuclide emitter; beta particle source)
01
Overview
Yttrium-90 is a radioactive isotope of yttrium that undergoes beta-minus decay to stable zirconium-90 with a half-life of about 64 hours and a maximum beta energy of 2.28 MeV; it is used therapeutically to deliver localized beta radiation, most commonly via microspheres for transarterial radioembolization in hepatocellular carcinoma and via antibody conjugates such as ibritumomab tiuxetan in lymphoma; it is not a biological receptor or enzyme but a radionuclide radiation source employed in targeted radiotherapy modalities
- Other names
- Yttrium-9090YY-90 radiationYttrium-90 radionuclide therapyYttrium-90 radioembolization (colloquial for the treatment modality)
02
Mechanism of action
Beta particle emission from Y-90 delivers localized ionizing radiation to tumor tissue, inducing DNA damage (including double-strand breaks) and subsequent tumor cell death when carried by antibodies or microspheres to the target site
03
Biological functions
Other (physical beta-emitter delivering cytotoxic ionizing radiation; causes DNA double-strand breaks and cell death when localized to tumors)
04
Disease associations
Cancer
05
Safety considerations
Non-target embolization causing gastrointestinal ulcers if microspheres lodge in stomach/duodenumprocedure-related infection and contrast allergy risksradiation-induced liver disease and hepatotoxicity as adverse effects of Y-90 radioembolization (recognised risks in locoregional therapy)
06
Interacting drugs
Ibritumomab tiuxetan (Zevalin)
2 more in the full profile.
07
Biomarkers
Hepatic tumor vascularity and tumor-to-liver perfusion ratio used in patient selection for Y-90 radioembolizationportal vein thrombosis statuslesion number and size in HCC (e.g., ≤8 cm solitary lesions in LEGACY study criteria) as predictors/selection factors
Beyond the preview
Go deeper on Yttrium-90 beta radiation (Y-90).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Yttrium-90 beta radiation (Y-90).